Natera, Inc. (NTRA)

Nasdaq · Austin, Texas, USA · Founded 2004 · CEO Steve Chapman

Valuation summary

$59.35 fair value versus $289.92 in the market, a difference of -79.5%. Rated Sell.

Fair value per share$59.35
Current share price$289.92
Upside / downside-79.5%
Bear case$38.65
Bull case$90.23
Discount rate (WACC)10.4%
Terminal growth3.20%
Market capitalisation$42B
EV / Sales14.7x

About Natera, Inc.

Founded in 2004 by Matthew Rabinowitz and Jonathan Sheena. Steve Chapman has been chief executive since 2019. Natera runs genetic tests on fragments of DNA found in a blood sample. Panorama screens pregnancies for chromosomal conditions, Signatera checks cancer patients after treatment for traces of tumour DNA that signal a relapse, and Prospera monitors organ transplants. Signatera volumes have been growing very quickly.

Investment case

  • The leader in tests that detect cancer recurrence from blood, a young and fast-growing market.
  • Insurance coverage keeps widening to more cancer types.
  • Has turned cash-flow positive as volumes scale.

Key risks

  • Revenue depends on what insurers and Medicare agree to pay.
  • Guardant, Exact Sciences and others are competing in cancer testing.
  • Patent disputes with rivals are ongoing.

Revenue by segment

Testing (women's health, oncology, organ health)99%
Licensing and other1%

Five-year forecast

RevenueFree cash flow
Year 1$3.7B$0.2B
Year 2$4.9B$0.3B
Year 3$6.1B$0.4B
Year 4$7.1B$0.5B
Year 5$7.7B$0.5B

What the street says

A favourite growth stock in diagnostics; the valuation assumes years of rapid expansion.

Comparable companies: ALNY · HUM · CNC · TEM · DXCM · ARGX · MDLN · HIMS

Open the interactive model, price chart and sensitivity grid →